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Abstract
The aggregation of a-synuclein (a-syn) into amyloid fibrils is associated with neurodegenerative diseases,
collectively referred to as the a-synucleinopathies. In vivo, molecular chaperones, such as the small heatshock proteins (sHsps), normally act to prevent protein aggregation; however, it remains to be determined
how aggregation-prone a-syn evades sHsp chaperone action leading to its disease-associated deposition.
This work examines the molecular mechanism by which two canonical sHsps, aB-crystallin (aB-c) and
Hsp27, interact with aggregation-prone a-syn to prevent its aggregation in vitro. Both sHsps are very
effective inhibitors of ¿-syn aggregation, but no stable complex between the sHsps and a-syn was
detected, indicating that the sHsps inhibit a-syn aggregation via transient interactions. Moreover, the
ability of these sHsps to prevent a-syn aggregation was dependent on the kinetics of aggregation; the
faster the rate of aggregation (shorter the lag phase), the less effective the sHsps were at inhibiting fibril
formation of a-syn. Thus, these findings indicate that the rate at which a-syn aggregates in cells may be a
significant factor in how it evades sHsp chaperone action in the a-synucleinopathies.
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ABSTRACT
The aggregation of α-synuclein (α-syn)
into amyloid fibrils is associated with
neurodegenerative diseases, collectively referred
to as the α-synucleinopathies. In vivo, molecular
chaperones, such as the small heat-shock proteins
(sHsps), normally act to prevent protein
aggregation; however, it remains to be determined
how aggregation-prone α-syn evades sHsp
chaperone action leading to its disease-associated
deposition. This work examines the molecular
mechanism by which two canonical sHsps, αBcrystallin (αB-c) and Hsp27, interact with
aggregation-prone α-syn to prevent its aggregation
in vitro. Both sHsps are very effective inhibitors of
α-syn aggregation, but no stable complex between
the sHsps and α-syn was detected, indicating that
the sHsps inhibit α-syn aggregation via transient
interactions. Moreover, the ability of these sHsps
to prevent α-syn aggregation was dependent on the
kinetics of aggregation; the faster the rate of
aggregation (shorter the lag phase), the less
effective the sHsps were at inhibiting fibril
formation of α-syn. Thus, these findings indicate
that the rate at which α-syn aggregates in cells
may be a significant factor in how it evades sHsp
chaperone action in the α-synucleinopathies.

INTRODUCTION
α-Synuclein (α-syn) is a protein primarily
found in neuronal tissue, where it is predominantly
localised to presynaptic terminals (1). The
definitive function of α-syn is yet to be
established, however it has been implicated in
modulating synaptic activity through membrane
processes, including membrane biogenesis,
vesicular trafficking and neurotransmitter release
(2,3). Although it has traditionally been considered
an intrinsically disordered protein (4,5), there have
been recent studies indicating that it may form an
alpha-helical tetramer in vivo (6,7). In addition, αsyn aggregates to form amyloid fibrils under
physiological conditions. The deposition of
fibrillar α-syn into inclusion bodies, known as
Lewy bodies or Lewy neurites when they are
present in the cell body or processes respectively,
is a pathological hallmark of a number of
neurodegenerative
disorders,
including
Parkinson’s disease, dementia with Lewy bodies
and multiple system atrophy, collectively referred
to as the α-synucleinopathies (8). Moreover,
multiplication of SNCA, which encodes for α-syn,
or missense mutations (A53T, A30P and E46K) in
this gene, cause familial early-onset Parkinson’s
disease (9-11). Under conditions of physiological
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pH and temperature, purified recombinant α-syn
forms fibrillar aggregates in vitro via a nucleationdependent mechanism (12). The lag phase in this
process, which is the rate-limiting step,
corresponds to the formation of oligomeric nuclei
from aggregation-prone intermediates. This is
followed by the rapid growth of nuclei into
fibrillar species (elongation phase) until
thermodynamic equilibrium is reached (plateau
phase) between monomeric and aggregated α-syn
forms (13).
While the main component of Lewy
bodies and Lewy neurites is α-syn, auxiliary
proteins, including small heat-shock proteins
(sHsps), have also been identified in these
inclusions (14-16). The expression of sHsps is
dramatically upregulated in response to cellular
stress (17), ageing (18) and in some protein
aggregation disorders, including the αsynucleinopathies (15). The sHsps are an integral
component of the cellular network that acts to
maintain protein homeostasis (proteostasis)
(19,20). This family of molecular chaperones is
defined by the relatively small molecular mass of
their monomeric subunits and the presence of a
central, conserved α-crystallin domain, which is
flanked by variable N- and C-terminal regions
(21). The sHsps are often referred to as ‘holdase’
chaperones, although this does not fully describe
their chaperone action (22). The sHsps prevent
protein aggregation by recognising, interacting
with and stabilising partially folded (hydrophobic)
intermediate states of target proteins that have left
the protein on-folding pathway and entered an offfolding pathway (23-25). As their chaperone
action is ATP-independent, sHsps are specialised
for preventing inappropriate associations that
could otherwise lead to aggregation in the energydepleted cell (26). A defining feature of some
mammalian sHsps (there are 10 in humans,
HSPB1-10), such as Hsp27 (HspB1) and αBcrystallin (αB-c; HspB5), is that they form large
polydisperse oligomers in solution which undergo
rapid subunit exchange (27,28). The consensus
model of sHsp chaperone action is that small,
dissociated species are the chaperone active
species as these likely contain a higher relative
degree of exposed hydrophobicity than the larger
oligomers (27). The larger oligomers are therefore
regarded as reservoirs of these chaperone-active
dissociated forms. Based on this model, the rate of

subunit exchange governs the speed of production
of chaperone-active species capable of interacting
with aggregation-prone states of target proteins.
Phosphorylation at three key residues, Ser15,
Ser45 and Ser59 in αB-c (29) or Ser15, Ser78 and
Ser82 in Hsp27 (30,31), has been suggested to be
an additional regulatory mechanism with regards
to chaperone function of sHsps during times of
cellular stress (32-34).
The ability of sHsps such as αB-c and
Hsp27 to prevent the fibrillar formation of α-syn
in vitro is well established (35-37). However, the
mechanism by which sHsps achieve this inhibition
remains to be definitively established (38).
Moreover, given the α-synucleinopathies (and
other diseases) are associated with protein
aggregation, it is clear that, under certain
circumstances, aggregation-prone proteins can
evade the chaperone action of the sHsps. This
failure of the sHsps to prevent aggregation is often
attributed to them being “overwhelmed” in the
context of disease (39-41). However, specific
factors that lead to sHsp chaperone activity being
overwhelmed are yet to be determined. In this
study, we have directly addressed this by
characterising the nature of the interaction
between the archetypal sHsps, αB-c and Hsp27,
and monomeric α-syn. We show that these
chaperones prevent α-syn aggregation through
transient interactions and that the chaperone
efficacy of these sHsps in preventing α-syn fibril
formation is highly dependent upon the rate at
which α-syn aggregates.
RESULTS
sHsps inhibition of α-syn aggregation is
concentration dependent – The amyloid fibrillar
aggregation of wild-type α-syn has been well
characterised in vitro (35). As expected, there was
no increase in Thioflavin-T (ThT) fluorescence
when Hsp27, BSA or buffer were incubated alone.
However, incubation of α-syn under these
experimental conditions resulted in an increase in
ThT fluorescence over time indicative of fibril
formation (Figure 1A). This increase in ThT
fluorescence was inhibited by the addition of
Hsp27 at a 1:1 (α-syn:Hsp27) molar ratio, but was
not inhibited by the presence of the non-chaperone
control protein bovine serum albumin (BSA). The
change in ThT associated with α-syn aggregation
can be fitted by a Boltzmann sigmoidal curve.
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This reveals that when α-syn was incubated alone
there was a lag phase of 15  3 h, and the
maximum ThT fluorescence occurred after 36  3
h (Figure 1B). Addition of the sHsps αB-c and
Hsp27 prevented the fibrillar aggregation of α-syn
in a concentration-dependent manner (Figure 1B).
At a 1:10 molar ratio (sHsp:α-syn), αB-c and
Hsp27 inhibited the change in ThT fluorescence
associated with α-syn fibril formation by 65 ± 4%
and 74 ± 5% respectively (Figure 1C).
In preventing the fibrillar aggregation of
α-syn the sHsps do not form stable, high molecular
mass sHsp-target protein complexes – To
investigate whether the sHsps inhibit the fibril
formation of α-syn via the formation of high
molecular mass complexes, as has been reported
for the interaction with amorphously aggregating
proteins (22,42,43), the samples containing a 1:1
molar ratio (i.e. a concentration corresponding to
near complete inhibition of fibril formation of αsyn, see Fig. 1B) were collected after the
aggregation assay for subsequent analysis by sizeexclusion chromatography (Figure 2A). Prior to
incubation, in the absence of sHsp, α-syn eluted
from the column in a peak centred at 17 mL.
Following incubation of α-syn in the absence of
sHsp, there was very little soluble α-syn present in
the sample, consistent with its aggregation into
fibrils. When present alone in solution, αB-c
eluted as a well resolved peak at 13 mL, consistent
with it being a large polydisperse oligomer of
average mass ~650 kDa under these solution
conditions (44,45). In the sample containing both
αB-c and α-syn, there was no detectable shift in
the elution volume or size of the individual peaks
corresponding to monomeric α-syn and oligomeric
αB-c, or the appearance of any additional peaks.
Thus, there was no significant difference in the
amount of soluble oligomeric B-c and
monomeric -syn in this sample compared to
when each of these (non-aggregated) proteins were
analysed alone. The presence of only αB-c in the
peak eluting at 13 mL and only α-syn in the peak
eluting at 17 mL in this sample was confirmed by
immunoblotting (Figure 2B) (the detectable limits
of the immunoblotting procedure used in this work
was ~30 nM for each protein). Even when a
crosslinker, bis[sulfosuccinimydyl] (with a spacer
arm length of 8 atoms or 11.4 Å), was added to the
sample following incubation and prior to size

exclusion chromatography, there was no evidence
of co-elution of αB-c and α-syn from the column
(data not shown). Thus, under the conditions used
in this work, we found no evidence of a stable
high-molecular mass complex formed between
B-c and aggregation-prone α-syn. Similar results
were obtained for samples containing Hsp27 and
α-syn (Figure 2B, D).
We sought to further investigate the
interaction between these sHsps and aggregationprone α-syn by analytical ultracentrifugation
(AUC). Due to the propensity of the wild-type
sHsps to form large, high molecular mass,
polydisperse oligomers in solution (see Fig 2A),
variant forms of these sHsps that either mimic
phosphorylation (Hsp273D) or consist of only the
core -crystallin domain (αB-ccore) were selected
for use in these experiments. This is because these
variants exist predominately as either monomers
or dimers (46,47) and therefore their molecular
masses more closely match that of α-syn (an
important factor in these absorbance-based AUC
experiments as it ensures that both species
sediment at similar rates). We first established that
both these variant forms also inhibit the fibrillar
aggregation of α-syn at similar levels to the wildtype proteins (Figure 3A). Notably, the ability of
the core domain (i.e. αB-ccore) to inhibit α-syn
aggregation indicates that the ability of the sHsps
to prevent α-syn fibril formation is inherent to the
α-crystallin domain, and does not require the N- or
C-terminal regions.
Sedimentation velocity (SV) profiles for
α-syn alone, and in the presence of either Hsp273D
or αB-ccore are shown in Figure 3. These profiles
were fitted using a c(s) model which considers
both sedimentation and diffusion to determine
sedimentation coefficients for the species in
solution (48). Single peaks for α-syn, αB-ccore and
Hsp273D correspond to sedimentation coefficients
of approximately 1.1, 1.7 and 2.7 S respectively.
Fitting the SV profile resulting from co-incubation
of α-syn with αB-ccore (Figure 3D) results in a
bimodal distribution, with peak positions of
approximately 1.2 and 1.9 S (Figure 3E). The
small shift of the peak positions may suggest that
these proteins interact transiently. Comparison of
the predicted weight-average sedimentation
coefficient for the two components with the
weight-average
sedimentation
coefficient
calculated for the mixture shows a small shift from
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1.37 S to 1.40 S. Similarly, co-incubation of α-syn
with Hsp273D (Figure 3F) results in a bimodal
distribution, with peaks corresponding to
sedimentation coefficients of approximately 1.1
and 2.7 S (Figure 3G). In contrast to the mixture of
α-syn with αB-ccore, the peak positions for α-syn
and Hsp273D do not change significantly. The
absence of additional peaks confirms the lack of a
detectable stable complex between these two
proteins.
The use of fluorescently labelled protein
allows specific detection of one component of a
complex mixture using fluorescence detected
AUC. As such, CF488A-labelled wildtype Hsp27
was used in fluorescence-based AUC experiments
to obtain SV profiles with a range of α-syn
concentrations (Figure 4). As above, these profiles
were fitted using the c(s) model and the resulting
distribution had three maxima (Figure 4B). The
shoulder centred at 0.9 S results from nonsedimenting fluorescence, and is attributed to
residual free CF488A dye in solution from the
labelling process. The other two main peaks,
centred at approximately 2.4 and 10.5 S, reflect
the equilibrium characteristic of wildtype Hsp27 in
which smaller species (most likely predominately
dimers) dissociate from polydisperse oligomers in
order to provide chaperone-active subunits (27).
Importantly, with increasing unlabelled α-syn
concentration, there is no concentration-dependent
increase in the weight-average sedimentation
coefficient that would otherwise be indicative of a
stable, high molecular mass complex being formed
between Hsp27 and α-syn. Rather, the weightaverage sedimentation coefficient decreases as the
concentration of α-syn increases (Figure 4C),
indicating that the average size of Hsp27 species
in solution decreases with increasing amounts of
α-syn. This trend is supported by a reduction in the
signal at 10.5 S and an increase in the signal at 2.4
S
with
increasing
(unlabelled)
-syn
concentration. Together, these data suggest that
the presence of aggregation-prone α-syn causes
the dissociation of Hsp27 polydisperse oligomers
in a concentration-dependent manner.
The ability of sHsps to prevent the
aggregation of α-syn is dependent on the kinetics
of the aggregation process – We next sought to
identify possible mechanism(s) by which
aggregation-prone α-syn may ‘overwhelm’ sHsps,
leading to the formation of amyloid fibrils

associated with disease. To determine whether the
rate at which α-syn aggregates affects the ability
of the sHsps to prevent fibril formation, we used
two methods to alter the kinetics of aggregation of
α-syn which avoid the confounding effect a
change in solution conditions (e.g. pH,
temperature) may have on the chaperone activity
of the sHsps (28,49-51). First, we exploited the
nucleation-dependent mechanism of amyloid fibril
formation of α-syn, whereby an increase in the
concentration of aggregation-prone protein
increases the rate of aggregation (13). Since the
dissociation of small chaperone-active species
from larger polydisperse oligomers is proposed to
be a key component of the chaperone activity of
sHsps (33,52,53), we also determined the rate of
subunit exchange over the sHsp concentration
range to be used in these experiments (i.e. 3 – 90
µM) using FRET. During subunit exchange,
mixing of labelled and unlabelled sHsp subunits
resulted in an exponential decrease in the emission
fluorescence intensity of the acceptor, which can
be used to calculate the rate of subunit exchange
(Figure 5A). Over the concentration range used in
this work, the rate of subunit exchange of αB-c
reached a maximum at ~30 µM (Figure 5B).
Importantly, this rate was not significantly
affected by the presence of α-syn (Figure 5B). In
contrast to αB-c, the oligomeric state of Hsp27
(46) and its subunit exchange rate (Figure 5C) are
both significantly affected by concentration.
Therefore, Hsp27 was unsuitable for use in these
experiments due to these confounding effects.
The disease-associated A53T variant of αsyn was incubated at concentrations from 150 –
750 µM in the absence and presence of αB-c
(Figure 5D). In the absence of the chaperone,
increasing the concentration of α-syn led to an
increase in the rate and maximum ThT
fluorescence associated with α-syn fibril
formation, and a decrease in the lag phase (from 9
± 2 h to 3 ± 1 h over this concentration range).
When αB-c was present, such that the molar ratio
of α-syn:αB-c remained constant (i.e. 1:10 αB-c:αsyn), the ability of αB-c to inhibit α-syn fibril
formation was dependent on the kinetics of the
aggregation process (Figure 5E-F). Thus, when the
kinetics of α-syn aggregation were relatively slow
(i.e. longer lag phase and slower rate of
aggregation), αB-c was a more effective inhibitor
of aggregation. When the kinetics of aggregation
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increased (i.e. shorter lag phase and faster rate of
aggregation), αB-c was a less effective chaperone,
only decreasing the amount of aggregation of αsyn by ~20%.
The second method employed to alter the
aggregation kinetics of α-syn aggregation was the
use of disease-related mutants which aggregate at
different rates (35). Recombinant α-syn mutant
proteins were incubated at 300 µM in the absence
or presence of either αB-c or Hsp27 (1:10 molar
ratio, sHsp:α-syn). As expected, each of the
mutant proteins displayed different aggregation
kinetics, with α-synA30P having a similar lag
phase, elongation rate and maximal fibril
formation to that of α-synWT (Figure 6A). In
contrast, α-synA53T had the shortest lag phase (3
 1 h), slowest elongation rate and lowest
maximum increase in ThT fluorescence. The αsynE46K variant was characterised by a slow rate
of elongation, high maximal ThT fluorescence,
and longest lag phase (42  9 h) of any of the αsyn variants tested. Whilst both αB-c and Hsp27
were able to inhibit the aggregation of the α-syn
proteins (Figure 6A), their ability to do so was
dependent upon the isoform of α-syn. Both
chaperones were least effective at inhibiting the
aggregation of α-synA53T, which aggregated the
fastest (i.e. shortest lag phase), whereas they were
most effective at inhibiting α-synE46K, which
aggregated the slowest (Figures 6B and C).
DISCUSSION
The sHsps play a critical role in
maintaining cellular proteostasis by preventing
protein aggregation associated with disease. Here,
we confirm that the sHsps αB-c and Hsp27 are
potent inhibitors of α-syn fibril formation in vitro
(37,54,55). The phosphomimicking variant of
Hsp27 was also an effective chaperone at
inhibiting α-syn fibril formation, adding to the
work demonstrating that phosphorylation of sHsps
acts to increase their chaperone activity (56).
Notably, the αB-c core domain inhibited the
aggregation of α-syn with similar efficacy to the
wild type (full length) protein, demonstrating that
the sites required to inhibit α-syn aggregation are
present in the core domain of these sHsps. The
finding that the core domain of B-c is sufficient
to prevent -syn aggregation is consistent with
previous studies showing that this region is

capable of preventing other target proteins from
forming amorphous or fibrillar aggregates (47,57).
Although the ability of the sHsps to inhibit
the amyloid fibrillar aggregation of a range of
target proteins in vitro is well established, the
mechanism by which they do so is not clearly
defined and may be dependent on the target
protein (22,58-60). We therefore sought to
characterise the molecular mechanism by which
αB-c and Hsp27 interact with α-syn to prevent its
aggregation. Our findings that both Hsp27 and αBc increase the lag phase of α-syn aggregation and
inhibit the elongation phase suggest that they
primarily act through stabilising aggregation-prone
monomeric α-syn to prevent it forming fibrils.
However, we were unable to detect a high
molecular mass complex formed between α-syn
and αB-c or Hsp27 under the experimental
conditions used in this work. Thus, in the absence
of any evidence of a stable interaction, we
conclude that these proteins interact transiently
and this acts to prevent α-syn aggregation.
Transient interactions between the sHsps
and α-syn are difficult to detect. Small shifts in the
c(s) distributions and calculated weight-average
sedimentation coefficient for the α-syn/αB-ccore
mixture may suggest a transiently interacting,
rapidly exchanging system. That these shifts were
not observed for Hsp273D does not rule out that αsyn and Hsp273D interact transiently. Rather it
indicates that this interaction was below the
detection limit of the AUC experimental
conditions. This may be due to differences in the
binding kinetics or the amount of α-syn interacting
with Hsp273D compared to αB-ccore. If the fraction
of species in this interacting population is too
small, or if the interaction occurs too fast, it may
not be able to be resolved in the sedimentation
experiment (61-63). Transient interactions
between αB-c and α-syn (and also of αB-c with
other fibril-forming target proteins) are apparent
from NMR spectra acquired on mixtures of these
proteins due to general broadening of spectra of
the target protein with no indication of specific
binding site(s) (37,64-66). We therefore conclude
that these sHsps prevent α-syn aggregation via
transient interactions in a similar way as has been
previously described for apoC-II and reduced and
carboxymethylated α-lactalbumin (22). In doing
so, the manner by which these sHsps act as
chaperones to prevent α-syn aggregation is not
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through a ‘holdase’ mechanism, as has been well
characterised
for sHsp interaction with
amorphously aggregating target proteins under
stress conditions, particularly elevated temperature
(42,43). Rather, these data support a model in
which sHsps can act as protein stabilisers,
interacting transiently with relatively ordered
protein intermediates that have entered off-folding
pathways, which facilitates them re-entering the
on-folding pathway (67). Considering the cellular
implications of this type of interaction, a transient
mechanism is favourable as it does not deplete the
pool of sHsps available to interact with
aggregation-prone proteins in the cells. In contrast,
a holdase-type chaperone mechanism, in which
stable high molecular mass complexes are formed,
occurs with more disordered intermediates that
expose higher degrees of hydrophobicity prior to
undergoing hydrophobic collapse and aggregation,
as occurs under significant stress conditions with
the formation of amorphous aggregates (22).
Importantly, it is unclear at this stage
whether the interaction between the sHsps and αsyn impacts the conformation of aggregationprone monomeric α-syn. However, previous
studies have demonstrated that depletion of B-c
from aggregation-inducing conditions containing
amyloidogenic substrate can allow aggregation to
proceed (22). This implies that transient
interactions between aggregation-prone species
and sHsps may not significantly alter the
conformation or aggregation propensity of the
target protein.
Our previous work has extensively
investigated the interaction of αB-c with a variety
of amorphously aggregating target proteins under
conditions of elevated temperature, reductive and
chemical stress. As a result of these studies, it is
apparent that there are similarities between the
mechanisms of sHsp chaperone interaction with
amorphous and fibrillar aggregating target
proteins. As observed in the current study with
fibril-forming α-syn, sHsps are more efficient
chaperones when interacting with slowly
(amorphously) aggregating target proteins
(68,69). They also interact with target proteins
early along their aggregation pathway, i.e.
monomeric forms that are in a disordered,
intermediate state (68,69). Dynamic, transient
interactions between the target protein and the

sHsp are also crucial factors in determining
chaperone efficacy with target proteins (70).
Given that both αB-c and Hsp27 are
highly effective molecular chaperones at inhibiting
α-syn fibril formation in vitro, the question
remains as to how α-syn intermediates escape the
sHsps to form fibrils and plaques in the context of
the α-synucleinopathies? A key factor explored in
this study was whether the rate of aggregation has
a significant effect on the ability of these
chaperones to prevent aggregation. Similar to the
reported effect of metals (71), pesticides ,
membrane lipids (72) and molecular crowding
(73,74), increases in the initial monomer
concentration of α-syn promotes nucleation during
the rate-limiting step, increasing the kinetics of
aggregation (73,75-77). Furthermore, the three
most studied disease-related mutations in α-syn
exhibit markedly different aggregation kinetics
(35), which was also observed in this study. We
therefore exploited both increases in α-syn
monomer concentration and disease-related
mutants of α-syn in order to alter the kinetics of
fibrillar aggregation of α-syn. In both cases,
increasing the rate of α-syn aggregation led to a
decrease in the chaperone ability of αB-c and
Hsp27 to prevent fibril formation. In particular,
there was a marked correlation between the
efficacy of the chaperone and the lag phase of
aggregation, i.e. the longer the time taken to form
nuclei, the more efficacious the chaperones were
in preventing aggregation. These results also
support our previous work in which we increased
the rate of α-syn fibril formation by adding the
inert crowding agent dextran, under which
conditions αB-c was a much poorer chaperone
(37). However, the presence of crowding agent
also reduces the rate of subunit exchange of αA-c
(78), which may have contributed to the decrease
in chaperone efficacy of αB-c in this case.
The effect of aggregation kinetics on the
ability of sHsps to prevent fibril formation is
significant given the association of mutations and
duplication or triplication of the SCNA gene with
early onset Parkinson’s disease (9-11,79,80).
Moreover, the link between increased aggregation
rate and a decrease in chaperone inhibition
provides a potential mechanism for aggregationprone α-syn overwhelming the chaperone
capability of the sHsps. While fluorescence-based
AUC suggested that the presence of aggregation-
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prone α-syn causes the dissociation of Hsp27
oligomers, this technique provides a measure of
the oligomeric distribution at equilibrium. The
real-time availability of chaperone-active subunits,
through their dissociation from large polydisperse
oligomers, which are able to interact with
aggregation-prone proteins, is governed by the
subunit exchange rate (81). The rate of subunit
exchange for αB-c increased with concentration up
to ~30 M, after which it remained constant,
which supports the notion that subunit exchange is
a result of dissociation from sHsp oligomers, as
opposed to oligomeric collisions, similar to that
demonstrated for αA-crystallin (28). Moreover,
factors that increase the rate of α-syn aggregation
in cells (such as mutation, gene multiplication or
macromolecular crowding) overwhelm the
protective capacity of the sHsps due to an
insufficient supply of chaperone-active subunits
capable of interacting with the aggregation-prone
α-syn monomer. Such a mechanism is also
consistent with the dissociated subunits of sHsps
being the chaperone-active species in cells.
This study aimed to characterise the
interaction of sHsps with monomeric species. This
required the addition of chaperone to monomeric
samples before aggregation has commenced,
similar to many other studies examining sHsp
chaperone action (33,35,37,82). Recently, the
interaction of sHsps with preformed amyloid
fibrils has also been investigated, and αB-c has
been shown to bind along the length of amyloid
fibrils with moderate (µM) affinity (36,83,84).
Addition of monomeric units to fibril ends is
essential during the elongation phase of
aggregation. In addition, sites of exposed
hydrophobicity along the face of the fibril have
been identified as possible locations for secondary
nucleation (via fragmentation), leading to rapid
fibril growth and dominating the overall kinetics
of aggregation (85-87). Interaction with these
species may contribute to the ability of sHsps to
inhibit aggregation, by competing with monomeric
units for access to fibril ends or occluding sites of
potential secondary nucleation (36). These
mechanisms undoubtedly play a role in the sHsp
inhibition of α-syn aggregation, and may
complement the interaction of the sHsps with
monomeric α-syn.
The current study contributes to a greater
understanding of the molecular mechanisms by

which sHsps interact with disease-related target
proteins to prevent their aggregation. We provide
further support for the reclassification of the sHsps
as protein stabilisers rather than holdase
chaperones since the latter does not fully describe
the manner by which they can interact with
aggregation-prone proteins (22). Thus, although
the ability to form complexes with destabilised,
particularly amorphously aggregating, proteins is a
key element of their chaperone activity (26), this
work adds to a growing body of evidence
highlighting that this is not the only mechanism by
which sHsps inhibit protein aggregation
(22,35,37,58,65). Furthermore, we demonstrate
that the rate of aggregation is a significant factor
that governs the relative ability of αB-c and Hsp27
to prevent α-syn fibrillar aggregation. This
provides a potential rationale for how sHsp
chaperone activity is ‘overwhelmed’ in the context
of diseases associated with protein aggregation,
i.e. factors that increase the rate at which
aggregation occurs also compromise the ability of
sHsps to prevent it.
EXPERIMENTAL PROCEDURES
Materials – The pET24d or pET24a
bacterial expression vectors, containing the human
HSPB1 (Hsp27), HSPB5 (αB-c), or SNCA (α-syn)
genes, were used for expression of recombinant
wild-type proteins. Disease-related mutants of αsyn and sHsp variants used in this work were
produced via site-directed mutagenesis of the
wild-type gene (GenScript, Piscataway, USA). In
particular, a variant of Hsp27 designed to mimic
phosphorylation was generated by mutation of
serine residues to aspartic acid at sites that are
modified in vivo (i.e. Ser15Asp, Ser78Asp and
Ser82Asp) to produce Hsp273D. Plasmids for the
expression of the core domain of αB-c, i.e.
residues 68 – 153 (αB-ccore), was a kind gift from
Professor A. Laganowsky (Texas A&M Health
Science Center, USA). All recombinant proteins
were expressed in Escherichia coli BL21(DE3)
cells transformed with each plasmid, and purified
as described previously (12,88,89). Dithiothreitol
(DTT) was purchased from Amresco (Solon,
USA), and protein molecular mass standards used
in gel electrophoresis were Protein Precision Plus
Dual Colour obtained from Bio-Rad Laboratories
(Hercules, USA). Protein mass calibrants for size
exclusion chromatography, containing bovine
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thyroglobulin (670 kDa), bovine γ-globulin (158
kDa), chicken ovalbumin (44 kDa), horse
myoglobin (17 kDa) and vitamin B12 (1.35 kDa),
was also purchased from Bio-Rad Laboratories
(Hercules, USA). All other chemicals, including
Thioflavin T (ThT), were obtained from SigmaAldrich (St Louis, USA), unless otherwise stated.
Protein concentrations were determined using a
NanoDrop
2000c
spectrophotometer
(ThermoFischer Scientific, Waltham, USA), based
. %
upon
values of 0.44 M-1.cm-1 for α-syn
calculated using the ExPASy ProtParam tool (90),
0.83 M-1.cm-1 for αB-c and 1.65 M-1.cm-1 for
Hsp27 (91). Mouse monoclonal anti-αB-c
antibody (clone 1B6.1-3G4) and mouse
monoclonal anti-Hsp27 antibody (clone G3.1)
were purchased from Abcam (Cambridge, UK).
Both the mouse monoclonal anti-α-syn antibody
(clone Syn211) and the peroxidase conjugated
anti-mouse IgG secondary antibody were obtained
from Sigma-Aldrich (St. Louis, USA).
Aggregation assays – Fibrillar aggregation
of α-syn in the absence or presence of sHsps was
monitored using a ThT fluorescence assay via a
previously
described
method (33) with
adaptations. Briefly, α-syn was incubated at 300
µM in 50 mM phosphate buffer containing 100
mM NaCl (pH 7.4) and 0.01% sodium azide
unless otherwise indicated. Assays were conducted
in triplicate using clear 384 microwell plates
(Greiner Bio-One, Frickenhausen, Germany) with
each well containing 30 µL of sample. Plates were
incubated in a POLARstar OPTIMA plate reader
(BMG Labtechnologies, Melbourne, Australia) at
37oC, with the plate sealed to prevent evaporation.
The ThT fluorescence was measured using
excitation and emission filters of 440 nm and 490
nm respectively and readings were taken every
625 sec for a period of up to 60 h. Plates were
subjected to linear shaking at 600 rpm for 540 sec
after each reading.
At the end of each assay, data for the change in
ThT over time were fitted with Boltzmann
sigmoidal curves using GraphPad Prism v 4.02
(GraphPad Software Inc., San Diego, USA). Data
were only used when the R2 coefficient of
determination was > 0.8. Parameters from these
fits were used to derive the length of the lag phase
and rate of α-syn aggregation using equations
previously derived (92), with modification (Figure

7). The equation of the Boltzmann curve is given
as:
1
The slope of the line at any point is:

1
When t = t50 (i.e. the inflexion point, when the
elongation rate is maximal):

1
Therefore the rate of α-syn aggregation at t50 was
calculated according to the equation:

4

(1)

where Fi corresponds to the initial fluorescence
value, Ff corresponds to the final fluorescence
value, t50 refers to the time taken to reach half the
maximal fluorescence, and k describes the gradient
of the curve.
The lag phase (tlag) is when

4
(2)
To solve for b, at t50 (i.e. the mid-point between Ff
and Fi):
2
2

4

So substituting b into equation (2):
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4

2
4

Solving for tlag:
4
2
4
2
Therefore, tlag is determined using the equation:
4

2

The relative efficacy of the sHsps to inhibit α-syn
fibril formation was determined by calculating the
protection provided by each sHsp at the
conclusion of the assay, according to the
difference in maximum ThT fluorescence in the
absence and presence of the chaperone using the
equation:
%

∆

∆
∆

100

where I and Ichaperone correspond to the change in
ThT fluorescence of α-syn in the absence and
presence of the sHsp respectively. In each case,
samples were assayed in triplicate and the percent
protection is reported as a mean ± S.E.M of at
least 3 independent (biological) replicates.
Analytical size exclusion chromatography
– The nature of the interaction between the sHsps
and α-syn was analysed via size exclusion
chromatography of the samples at the end of the
aggregation assays. Samples containing 300 µM αsyn in the absence or presence of 300 µM αB-c or
Hsp27, were collected immediately following
incubation and centrifuged at 14 000 x g for 10
min at 4oC to remove any insoluble protein.
Supernatants were collected and loaded onto a
Superose-6 size exclusion column (GE Healthcare,
Uppsala, Sweden), pre-equilibrated with 50 mM
phosphate buffer containing 100 mM NaCl (pH
7.4) and 0.01% sodium azide, at a flow rate of 0.5

mL/min. Protein elution was monitored using an
in-line UV detector, and concentrations were
determined using the peak integration function of
PrimeView v5.0 (GE Healthcare, Uppsala,
Sweden), to monitor any loss of protein following
centrifugation. Eluate fractions (1 mL) were
collected and analysed via SDS-PAGE and
immunoblotting. Representative results are
presented from two independent experiments from
two separate aggregation assays.
Immunoblotting – Following SDS-PAGE,
in which proteins were resolved on 15% (v/v) gels,
proteins were transferred to nitrocellulose
membrane at 100 V for 1 h. Membranes were
blocked with 5% (w/v) skim milk powder in Trisbuffered saline (TBS; 10 mM Tris-HCl, 150 mM
NaCl, pH 7.5) for 1 h at room temperature. Blots
were then incubated with primary antibodies
directed against αB-c, Hsp27 or α-syn, diluted
1:5000 in 5% (w/v) skim milk powder in TBS
containing 0.05% Tween-20 (TBS-T) for 1 h at
room temperature. Blots were washed four times
(10 min) in TBS-T, and incubated with the
peroxidase-conjugated anti-mouse secondary
antibody (1:5000 dilution in 5% (w/v) skim milk
powder in TBS-T) for 1 h at room temperature.
Blots were washed as above and labelled proteins
were detected with SuperSignal West Pico
Chemiluminescent Substrate according to the
manufacturer’s
instructions
(ThermoFisher
Scientific, Waltham, USA).
Fluorescent labelling of sHsps –
Recombinant
proteins
of
interest
were
fluorescently labelled with either succinimidyl
ester or maleimide variants of CF488A or CF647
dyes (Biotium, Hayward, USA) according to the
manufacturer’s instructions. Briefly, those samples
intended for maleimide labelling were preincubated with a 10 fold molar excess of Tris(2carboxyethyl)phosphine (TCEP) for 30 min at
room temperature. Recombinant protein was then
loaded onto a PD10 column (GE Healthcare,
Uppsala, Sweden) pre-equilibrated with degassed
phosphate buffered saline (PBS; 2.7 mM KCl,
1.75 mM K2HPO4, 135 mM NaCl, 10 mM
NaH2PO4, pH 7.4) and 500 μL fractions were
collected. Protein elution was monitored by
determining the absorbance of each fraction at 280
nm. Fractions containing protein were pooled and
dye conjugates were added in a 1.5 molar
(succinimidyl ester) or 10 molar (maleimide)
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excess relative to the protein concentration for
labelling. Labelling reactions were incubated
overnight at 4oC with agitation, and then labelled
protein was separated from unreacted dye using a
pre-equilibrated PD10 column as described above.
The concentration and degree of labelling of each
protein were calculated as per the manufacturer’s
instructions and the latter was found to be greater
than 60% in all cases. Labelled proteins were
stored at -20oC. Protein labelling with the
fluorophore was also confirmed via electrospray
ionisation mass spectrometry.
Analytical ultracentrifugation (AUC) –
UV absorbance-detected AUC was performed as
previously described (83). Briefly, the maximum
concentration was calculated for each protein such
that the absorbance at 230 or 280 nm was within
the optimal detection range of the instrument.
Samples (380 µL) were prepared at room
temperature and incubated for 1 h before being
loaded into a 12 mm double-sector epon-filled
centrepiece, alongside the relevant reference
solution (400 µL). Samples were centrifuged in an
XL-I analytical ultracentrifuge (Beckman Coulter,
CA, USA) at 50 000 rpm using either a Ti60 or
Ti50 rotor at 20oC. Radial absorbance scans were
collected at 230 nm or 280 nm at 6 min intervals
with a radial step size of 0.003 cm for a total of 10
h. Sedimentation velocity (SV) profiles were
analysed with SEDFIT software using a
continuous
c(s)
distribution
model
and
regularization by maximum entropy. Using a
regularisation parameter of p=0.95 and 200
sedimentation coefficient increments, the data
were fitted to produce c(s) distributions. Weightaverage sedimentation coefficients of each sample
were then calculated by integration of the
sedimentation distributions over the given range.
The buffer density (), buffer viscosity () and
partial specific volume () used for analysis were
estimated
using
SEDNTERP
software
(http://sednterp.unh.edu).
Fluorescence-detected AUC was performed as
previously described (83), using Hsp27-WT
labelled with CF488A and unlabelled, monomeric
α-syn. Briefly, samples (350 µL) were prepared at
room temperature and incubated for 1 h before
being loaded into a 12 mm double-sector eponfilled centrepiece, and covered with 50 µL of FC43 perfluorotributylamine (Scientific Instrument
Services Inc., NJ, USA). Samples were

centrifuged in an XL-A analytical ultracentrifuge
fitted with a fluorescence detection system (FDS;
Aviv Biomedical, NJ, USA) at 50 000 rpm using
either a Ti60 or Ti50 rotor at 20oC. Excitation was
at 488 nm and fluorescence above 505 nm was
measured. Radial fluorescence scans were
collected at 3 min intervals with a radial step size
of 0.002 cm for a total of 5 h. Sedimentation
velocity profiles were analysed as described
above, fitting time-independent noise and
according to a fixed sample meniscus position.
Bulk Förster Resonance Energy Transfer
(FRET) analysis of sHsp subunit exchange rate –
Subunit exchange rates of the sHsps were
determined by monitoring changes in Förster
Resonance Energy Transfer (FRET) between
fluorescently labelled sHsp oligomers. Aliquots of
fluorescently labelled sHsp, composed of an
equimolar mixture of CF488A- and CF647maleimide labelled protein, were prepared in PBS
(pH 7.4) at concentrations ranging from 3 – 90
µM. Samples were incubated at 37oC with shaking
at 60 rpm using a VorTemp incubator (Labnet,
Edison, USA) for 1 h, to allow complete mixing of
the two labelled populations (confirmed by
monitoring the quenching of donor fluorescence at
495 nm). The labelled sHsps were then diluted 10
fold into a sample of unlabelled sHsp at an
equivalent concentration so as to maintain the
overall concentration of the sHsp. The loss of
FRET due to subunit exchange of labelled sHsps
with unlabelled sHsps was determined by the
decrease in acceptor fluorescence at 670 nm and
monitored using a POLARstar Omega platereader
(BMG Labtechnologies, Melbourne, Australia).
Experiments were performed in the absence or
presence of a 10-fold molar excess of α-synWT, in
black polystyrene clear-bottom 384-well plates
(Greiner Bio-One, Frickenhausen, Germany).
Readings were taken every 120 s over a period of
4 h, with linear shaking at 600 rpm for 90 s after
each cycle. The rate constant was determined by
fitting the data to a one-phase exponential decay
curve using GraphPad Prism v 4.02 (GraphPad
Software Inc., San Diego, USA). The rate of
subunit exchange was derived from the equation:

where k is defined as the rate constant of the
reaction, and Y0 and Yt correspond to the
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fluorescence intensity at time = 0 and t

respectively.
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FIGURE LEGENDS
Figure 1: sHsp inhibit α-syn aggregation in a concentration-dependent manner. Recombinant α-syn
was incubated at 300 μM in 50 mM sodium phosphate buffer with 100 mM NaCl and 0.01% NaN3 (pH
7.4), in the absence or presence of sHsps or the non-chaperone control protein BSA. Fibril formation was
monitored by the change in ThT fluorescence at 490 nm over time. (A) A representative trace of 2
independent experiments is shown for α-syn in the absence or presence of Hsp27 or BSA at a 1:1 molar
ratio (Hsp27/BSA:α-syn). Hsp27, BSA and buffer alone samples are also included for comparison, and
the data for these overlay one another along the x-axis due to them showing no change in fluorescence
over the course of the assay. (B) A representative trace of 4 independent experiments is shown for α-syn
in the presence of various ratios of wildtype αB-c. Data were fitted with a Boltzmann sigmoidal curve
using GraphPad Prism v 4.02. (C) Values obtained for the maximum change in ThT fluorescence from
these fits was used to determine the percent protection afforded by wildtype αB-c or Hsp27 at a range of
molar ratios. Results are presented as mean ± S.E.M (n ≥ 4).
Figure 2: sHsps prevent α-syn aggregation but, in doing so, do not form a stable high molecular
mass sHsp-target protein complex. (A, B) Size-exclusion chromatograms of soluble α-syn (300 μM),
αB-c (300 μM), Hsp27 (300 μM) or post-aggregation samples of soluble α-syn (300 μM) in the absence
and presence of 1:1 molar ratio of αB-c or Hsp27. (C, D) Immunoblot analysis of the eluate fractions
collected from the size-exclusion column after loading with the sample from A or C containing α-syn and
αB-c or Hsp27. Aliquots from every fraction (1 mL) collected between 8–20 mL were loaded on to a
SDS/PAGE gel, transferred to nitrocellulose membrane and blotted with an anti-αB-c, anti-Hsp27 or antiα-syn antibody. Results shown are representative of two independent experiments.
Figure 3: Analysis of the interaction between sHsps and aggregation-prone α-syn by absorbancebased AUC. Recombinant α-syn was incubated at 300 μM in 50 mM sodium phosphate buffer with 100
mM NaCl and 0.01% NaN3 (pH 7.4), in the absence or presence of sHsps variants (30 µM). Fibril
formation was monitored by the change in ThT fluorescence at 490 nm over time, and data were fitted
with a Boltzmann sigmoidal curve using GraphPad Prism v 4.02. Sedimentation velocity analysis of 5 µM
(B) α-syn, (C) αB-ccore or (D) Hsp273D. Data collected at 60 min intervals is presented, overlaid with
theoretical fits to the c(s) model generated by SEDFIT. Sedimentation velocity profiles of α-syn coincubated with (E) αB-ccore or (G) Hsp273D are also shown, along with c(s) distributions for these profiles
(F and H respectively).
Figure 4: Aggregation-prone α-syn induces the dissociation of oligomeric Hsp27. Sedimentation
velocity analysis of 0.5 µM CF488-labelled Hsp27 in the absence or presence of increasing
concentrations of α-syn (0 – 50 µM). (A) Radial scans are displayed for the highest α-syn concentration
overlaid with theoretical fits to the c(s) model generated by SEDFIT. Data are collected at 60 min
intervals is presented. (B) c(s) distributions for each profile are shown, and (C) the weight-average
sedimentation coefficient was calculated via integration from 1 - 25 S for each concentration of α-syn.
Data were then fitted with a linear regression model.
Figure 5: The ability of αB-c to inhibit the fibrillar aggregation of α-syn is dependent on the kinetics
of aggregation. (A) Fluorescently labelled αB-c was incubated for 1 h at 37oC in PBS (pH 7.4) at
concentrations ranging from 3 – 90 µM, consisting of an equimolar mixture of fluorescently labelled
protein capable of FRET. Samples were diluted 10-fold into unlabelled α-Bc, in the absence or presence
of α-syn at a 1:10 (α-Bc:α-syn) molar ratio, and the loss of fluorescence in the acceptor fluorescence
channel was used to calculate (B) the rate of subunit exchange in the absence and presence of α-syn. (C)
The rate of subunit exchange was similarly calculated for Hsp27, in the absence and presence of α-syn.
(D) Recombinant A53T α-syn was incubated at concentrations ranging from 150 – 750 μM in 50 mM
phosphate buffer containing 100 mM NaCl and 0.01% NaN3 (pH 7.4), in the presence or absence of a
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1:10 molar ratio of αB-c. Samples were incubated at 37oC for 60 h and aggregation was monitored via the
change in ThT fluorescence at 490nm. A representative plot is shown for α-syn in the absence of αB-c
with Boltzmann-sigmoidal curves fitted to the data. Values obtained from D were used to calculate the lag
phase, elongation rate and plateau phase for each α-syn concentration. The percent protection afforded by
αB-c when present in the sample was calculated and correlated with the (E) duration of the lag phase and
(F) rate of elongation. Symbols represent the calculated parameters from each of three independent
repeats, with each point corresponding to values calculated from a fit of triplicate samples and shaded
according to the concentration of α-syn as indicated in panel D. Data in B, E and F were fitted with a nonlinear regression model and data in C were fitted with a linear regression model. The R2 coefficients of
determination are shown.
Figure 6: The ability of the sHsps αB-c and Hsp27 to prevent the aggregation of disease-associated
mutant forms of α-syn. Recombinant WT or disease-related mutant forms of α-syn (A30P, A53T or
E46K) were incubated at 300 μM in 50 mM phosphate buffer containing 100 mM NaCl and 0.01% NaN3
(pH 7.4), in the presence or absence of 30 μM αB-c or Hsp27. Samples were incubated at 37oC for 60 h
and aggregation was monitored via the change in ThT fluorescence at 490 nm. (A) Representative plots of
the four independent repeats, each consisting of triplicate samples, are shown for each of the α-syn
proteins, including Boltzmann-sigmoidal curves fitted to the data. Values obtained from these fits were
used to calculate the lag phase for each protein, which was then correlated with the percent protection
when (B) αB-c or (C) Hsp27 was present in the sample. Data shown are the results of four independent
repeats, with each point corresponding to values calculated from a fit of triplicate samples. Non-linear
regression analysis of the correlation between the lag phase and the percent protection was generated
using GraphPad Prism v 4.02.
Figure 7: Schematic illustration of the Boltzmann sigmoidal curve used to describe the increase in
ThT fluorescence upon α-syn fibril formation. Fi corresponds to the initial fluorescence value, Ff
corresponds to the final fluorescence value, t50 refers to the time taken to reach half the maximal
fluorescence (Ft50), tlag is the lag time and k denotes the steepness of the curve.
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